Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Triumph 1 Triumph 2 2026 Results Obesity Trial Data

Retatrutide triumph 1 triumph 2 2026 results obesity trial data reveal groundbreaking Phase 3 outcomes, with up to 28.7% average weight loss in TRIUMPH-4[1] and strong diabetes control in related trials[2]. These findings from Eli Lilly's triple agonist position retatrutide as a potential game-changer for obesity management, surpassing many GLP-1 therapies. As 2026 readouts unfold, they highlight efficacy in weight reduction, pain relief, and comorbidities like osteoarthritis and type 2 diabetes.

Introduction to Retatrutide Triumph 1 Triumph 2 2026 Results Obesity Trial Data

Retatrutide triumph 1 triumph 2 2026 results obesity trial data mark a significant milestone in the fight against obesity. Eli Lilly's Phase 3 TRIUMPH program has delivered topline results showing unprecedented weight loss and comorbidity improvements[1][2].

Overview of Retatrutide's Triple Agonist Mechanism

Retatrutide works as a triple hormone receptor agonist. It targets GIP, GLP-1, and glucagon receptors to boost insulin secretion, slow digestion, and increase energy use[5].

This mechanism goes beyond dual agonists like semaglutide. Early data suggest it drives more sustained weight loss without plateaus Eli Lilly[5].

The TRIUMPH Phase 3 Program: Targeting Obesity and Comorbidities

The TRIUMPH trials test retatrutide in real-world obesity scenarios. They include patients with knee osteoarthritis, sleep apnea, and type 2 diabetes[4].

Key trials like TRIUMPH-4 focus on obesity with osteoarthritis[1]. Others address diabetes and cardiovascular risks, providing broad retatrutide triumph 1 triumph 2 2026 results obesity trial data.

Why 2026 Results Are Pivotal for Obesity Treatment

2026 brings multiple Phase 3 readouts, including diabetes trials. These could confirm retatrutide's superiority over current options.

Analysts predict peak sales over $15 billion if approved. The data could reshape guidelines for obesity care GlobalData Forecast.

What is Retatrutide? Drug Profile and Development

Retatrutide is Eli Lilly's investigational drug for obesity. Its unique profile sets it apart in a crowded market.

Eli Lilly's Investigational Triple Receptor Agonist (GIP, GLP-1, Glucagon)

Developed by Eli Lilly, retatrutide activates three key receptors. GIP enhances insulin response, GLP-1 curbs appetite, and glucagon burns fat[5].

Phase 2 trials showed up to 24% weight loss[5]. Phase 3 builds on this with diverse populations ClinicalTrials.gov[4].

Administration: Once-Weekly Subcutaneous Injection

Patients self-administer retatrutide weekly via subcutaneous shot. Doses ramp up gradually to minimize side effects.

This convenience matches drugs like tirzepatide. It supports long-term adherence in obesity treatment.

Target Populations: Obesity, Overweight, Type 2 Diabetes, and Comorbidities

Retatrutide targets adults with BMI over 27 kg/m² and comorbidities. This includes osteoarthritis, sleep apnea, and cardiovascular disease[4].

Trials exclude those with certain conditions for safety. Results apply to common obesity profiles.

TRIUMPH-4 Trial Results: Record Weight Loss in Obesity with Knee Osteoarthritis

TRIUMPH-4 delivered stunning results in December 2025[1]. It tested retatrutide in obesity complicated by knee pain.

Trial Design: Phase 3, 68 Weeks, 9mg and 12mg Doses vs. Placebo

This global, double-blind study randomized patients to 9mg, 12mg retatrutide, or placebo. Duration was 68 weeks with gradual dose escalation[1].

Primary endpoints were weight loss and pain reduction. All were met convincingly Lilly Topline Release[1].

Key Efficacy: 28.7% Weight Loss (12mg), 26.4% (9mg), 75% Pain Reduction

At 12mg, participants lost 28.7% body weight on average—over 70 pounds[1]. The 9mg dose achieved 26.4%, far above placebo's 2.1%[1].

Knee pain dropped 75% via WOMAC scale[1]. Many reported complete pain relief, a rare outcome.

Over 12.5% on retatrutide had no knee pain vs. 4.2% placebo[1].
Physical function improved alongside weight loss.

Additional Benefits: CV Risk Markers, Physical Function, Blood Pressure

Retatrutide improved non-HDL cholesterol, triglycerides, and hsCRP. Physical function scores rose, aiding mobility[1].

Systolic blood pressure fell significantly. These cardiometabolic gains enhance its value NEJM Publication Pending[1].

TRIUMPH-1 Trial: 2026 Diabetes and Obesity Results

TRIUMPH-1 targeted type 2 diabetes patients with obesity. March 2026 data (aligned with TRANSCEND-T2D-1) showed robust results at 40 weeks[2].

Trial Focus: Type 2 Diabetes Patients with Obesity (40 Weeks)

Participants had poorly controlled diabetes despite lifestyle efforts. Baseline BMI averaged 35.8 kg/m²[2].

The trial assessed glycemic control and weight. No diabetes medications interfered Lilly Diabetes Readout[2].

Efficacy Data: Up to 16.8% Weight Loss, 2.0% HbA1c Reduction

Highest dose yielded 16.8% weight loss (-36.6 lbs) vs. 2.5% placebo[2]. HbA1c fell 2.0% points vs. 0.8%[2].

Weight loss continued without plateau[2]. For detailed TRIUMPH-1 80-week weight loss analysis.

No Weight Loss Plateau Observed Across Doses

Unlike some therapies, retatrutide sustained loss through 40 weeks[2]. This suggests potential for longer-term benefits.

Doses showed dose-response: low 11.5%, mid 15.5%, high 16.8%[2].

Dose	% Weight Loss	Absolute Loss (lbs)
Low	11.5%	24.5
Mid	15.5%	33.3
High	16.8%	36.6
Placebo	2.5%	6.2

TRIUMPH-2 Trial Status: Obesity, T2D, OSA, and OA Outcomes

TRIUMPH-2 remains ongoing as of early 2026[4]. It evaluates retatrutide in type 2 diabetes with obesity and comorbidities.

Ongoing Phase 3 Design for T2D Patients with Comorbidities

This trial mirrors TRIUMPH-1 but adds OSA and OA focus[4]. Patients have overweight or obesity plus diabetes.

Endpoints include weight, A1c, apnea severity, and pain. Recruitment continues globally.

Expected Endpoints: Weight Loss, Glycemic Control, Sleep Apnea Relief

Anticipated weight loss matches TRIUMPH-4 levels. Sleep apnea improvements could be key for obese patients.

OA pain reduction is another goal. See TRIUMPH trial results for obstructive sleep apnea.

Integration with Broader 2026 Readouts

TRIUMPH-2 feeds into seven expected 2026 completions[3]. These will solidify retatrutide triumph 1 triumph 2 2026 results obesity trial data.

Combined data could support broad labeling across obesity subtypes.

2026 Retatrutide Trial Readouts and Clinical Status Updates

2026 is a banner year for retatrutide. Multiple Phase 3 trials wrap up, building on TRIUMPH-4 success[3].

March 2026 Diabetes Trial Highlights (TRANSCEND-T2D-1/TRIUMPH-1)

The diabetes readout hit 16.8% weight loss at 40 weeks[2]. HbA1c drops were class-leading.

No plateau signals more loss ahead. This bolsters obesity-diabetes dual benefits.

Seven Additional Phase 3 Completions Expected

Lilly plans readouts in obesity, maintenance dosing, and more. CVD trial (NCT05882045) nears Week 80 weight data[3].

These will complete the Phase 3 package ClinicalTrials.gov NCT05882045[3].

Maintenance dosing trials to assess sustained loss post-titration.
Additional comorbidity studies for sleep apnea and heart risks.

Ongoing CVD Trial (NCT05882045): Week 80 Weight and CV Outcomes

This study tests retatrutide in obesity with heart disease[3]. Primary is 80-week weight change.

CV safety is key for approval. Early signals are positive, with improvements in lipids and blood pressure.

Efficacy Results: Weight Loss, Pain Reduction, and Beyond

Retatrutide triumph 1 triumph 2 2026 results obesity trial data emphasize superior efficacy. Weight loss exceeds 25% in key arms[1][2].

Dose-Specific Weight Loss Tables (9mg, 12mg, High Dose)

TRIUMPH-4 data shine[1]:

Dose	% Weight Loss	Placebo-Adjusted	Duration
12mg	28.7%	26.6%	68 weeks
9mg	26.4%	N/A	68 weeks
Placebo	2.1%	-	68 weeks

Diabetes trial high dose: 16.8% at 40 weeks, ongoing trajectory[2].

Comparisons to GLP-1s like Semaglutide: Superior 26-28% Loss

Semaglutide tops at ~20% in similar trials (e.g., STEP program). Retatrutide's glucagon boost pushes further without plateau[5].

Tirzepatide: ~22% max; retatrutide 28.7% sets new bar[1].
Proportions achieving ≥25% loss: majority on high dose. For cardiovascular benefits from related Triumph trials.

Pain relief (75% WOMAC reduction) adds unique value over weight-only drugs[1].

Proportions Achieving ≥25-35% Weight Reduction

In TRIUMPH-4, most on 12mg exceeded 25%[1]. Over a third hit 35%, transforming severe obesity.

≥25%: High rates across doses.
≥30-35%: Rare pre-retatrutide, now achievable for many.

Physical function and pain gains amplify impact, improving daily life.

Safety Data and Side Effects from Triumph Trials

Safety aligns with incretin class but includes new signals. Monitoring is ongoing as retatrutide triumph 1 triumph 2 2026 results obesity trial data incorporate full profiles[1].

Common GI Events: Nausea, Diarrhea, Discontinuation Rates (12-18%)

Nausea, diarrhea, and constipation were top issues, mostly mild-moderate during escalation.

Nausea: Most common, resolved over time.
Diarrhea/constipation: Dose-related, manageable with support.
Decreased appetite: Contributed to weight loss.

Discontinuations: 18.2% (12mg), 12.2% (9mg), vs. 4% placebo[1]. See phase 3 discontinuation rates and BMI insights.

Higher BMI correlated with lower rates in some analyses, suggesting tolerability in target groups.

Emerging Dysesthesia Signal in TRIUMPH-4

Dysesthesia—an odd touch sensation like tingling or numbness—appeared newly in TRIUMPH-4[1].

Its cause and severity are under review; not seen in Phase 2[1]. Full data will clarify impact. For full explanation of dysesthesia side effects Lilly Safety Update[1].

No link to serious outcomes yet; incidence details pending.

Overall Profile: Consistent with Incretin Class

Mild to moderate events predominate. No severe liver or pancreas signals reported.

Heart rate increases mild, monitored.
Hypoglycemia low without insulin use.
Long-term data from CVD trial (Week 80+) will inform durability[3].

Profile supports chronic use in obesity.

FDA Approval Timeline and Legal Status

Retatrutide triumph 1 triumph 2 2026 results obesity trial data position it strongly for regulators, though still investigational only. No approvals worldwide yet[4].

Current Status: Investigational, No Approval Yet

Phase 3 success paves the way. NDA filing likely post-2026 readouts. Check current FDA approval status for retatrutide.

Not available outside trials; compassionate use limited.

Predicted 2027 Launch with $15B+ Sales Potential

Analysts eye 2027 U.S. launch. Sales could hit $15.6B by 2031 GlobalData.

Blockbuster potential from superior efficacy.
Comorbidities like OA/OSA expand market.
Track retatrutide's global approval progress for EMA/TGA timelines.

Sourcing research‑grade retatrutide?

Ready to explore medical weight management?